

ADMA BIOLOGICS, INC.
Form 8-K
November 26, 2012

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 19, 2012

ADMA BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	000-52120 (Commission File Number)	56-2590442 (IRS Employer Identification No.)
65 Commerce Way Hackensack, New Jersey (Address of principal executive offices)		07601 (Zip Code)

Registrant's telephone number, including area code: (201) 478-5552

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.07 Submission of Matters to a Vote of Security Holders.

On November 19, 2012, an action by written consent by stockholders holding an aggregate of 2,907,141 shares of common stock, par value \$0.0001 per share (the “Common Stock”) of ADMA Biologics, Inc. (the “Company”) became effective. The corresponding action amended the Company’s 2007 Employee Stock Option Plan (the “2007 Plan”), which amendment provided for an increase in the number of shares of the Common Stock available for issuance under the 2007 Plan (including in relation to grants previously made) to key employees, or board members of, or consultants to, the Company, or any subsidiary of the Company, from 561,200 shares to 711,200 shares. Stockholders holding 1,715,690 shares of Common Stock were not asked to sign the consent.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

November 26, 2012

ADMA Biologics, Inc.

By: /s/ Adam S. Grossman
Name: Adam S. Grossman
Title: President and Chief
Executive Officer